脑膜瘤中的激素治疗:现状如何?
本文综述了激素与脑膜瘤关系的文献,并检索了MEDLINE PubMed、Scopus和NIH临床试验数据库中激素药物治疗脑膜瘤的临床试验。发现所有类固醇激素试验在多数患者中缺乏受体鉴定或阳性受体状态,而五项生长抑素类似物研究中有四项将阳性受体状态作为纳入标准。结论认为生长抑素类似物联合其他疗法的试验前景可期,但需重新评估激素单药治疗。
要点
- 多数脑膜瘤表达孕激素和生长抑素受体,其他受体结论尚不明确。
- 类固醇激素试验多数患者缺乏受体鉴定或阳性受体状态。
- 五项生长抑素类似物研究中四项以阳性受体状态为纳入标准。
核心结论
- 生长抑素类似物联合其他疗法的多项临床试验近期已完成或正在进行,结果似有前景,但需重新评估激素单药治疗。
- 作者提出未来试验可利用分级、受体状态和体细胞突变等特征进行患者分层,以选择最可能从特定治疗中获益的患者。
研究设计与样本
- 本文为文献综述,检索了MEDLINE PubMed、Scopus和NIH临床试验数据库中激素药物治疗脑膜瘤的临床试验。
主要发现
- 所有类固醇激素试验在多数患者中缺乏受体鉴定或阳性受体状态。
- 五项生长抑素类似物研究中有四项将阳性受体状态作为纳入标准。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Meningiomas are associated with several gonadal steroid hormone-related risk factors and demonstrate a predominance in females. These associations led to investigations of the role that hormones may have on meningioma growth and development. While it is now accepted that most meningiomas express progesterone and somatostatin receptors, the conclusion for other receptors has been less definitive. METHODS: We performed a review of what is known regarding the relationship between hormones and meningiomas in the published literature. Furthermore, we reviewed clinical trials related to hormonal agents in meningiomas using MEDLINE PubMed, Scopus, and the NIH clinical trials database. RESULTS: We identify that all steroid-hormone trials lacked receptor identification or positive receptor status in the majority of patients. In contrast, four out of five studies involving somatostatin analogs used positive receptor status as part of the inclusion criteria. CONCLUSIONS: Several clinical trials have recently been completed or are now underway using somatostatin analogs in combination with other therapies that appear promising, but a reevaluation of hormone-based monotherapy is warranted. Synthesizing this evidence, we clarify the remaining questions and present future directions for the study of the biological role and therapeutic potential of hormones in meningioma and discuss how the stratification of patients using features such as grade, receptor status, and somatic mutations, might be used for future trials to select patients most likely to benefit from specific therapies.
引用
- Miyagishima DF, Moliterno J, Claus E, et al. Hormone therapies in meningioma-where are we? J Neurooncol. 2022. PMID: 36418843. doi:10.1007/s11060-022-04187-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。